The aim of this study is to investigate the efficacy of 50 mg opicapone when administered
with the existing treatment of levodopa (L-dopa) plus a dopa decarboxylase inhibitor (DDCI),
in Parkinson's disease (PD) patients with end-of-dose motor fluctuations and associated pain